| Product Code: ETC8869833 | Publication Date: Sep 2024 | Updated Date: Feb 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Poland import trend for patient-derived xenograft (PDX) models saw a notable growth rate of 57.63%, with a compound annual growth rate (CAGR) of 30.04% from 2020 to 2024. This steep increase in imports could be attributed to a significant shift in demand towards PDX models for research and development purposes within the pharmaceutical and biotech industries in Poland.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Poland Patient Derived Xenograft (PDX) Models Market Overview |
3.1 Poland Country Macro Economic Indicators |
3.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, 2022 & 2032F |
3.3 Poland Patient Derived Xenograft (PDX) Models Market - Industry Life Cycle |
3.4 Poland Patient Derived Xenograft (PDX) Models Market - Porter's Five Forces |
3.5 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Type, 2022 & 2032F |
3.6 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Tumor Type, 2022 & 2032F |
3.7 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.8 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Technique, 2022 & 2032F |
3.9 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Poland Patient Derived Xenograft (PDX) Models Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Poland |
4.2.2 Growing demand for personalized medicine and targeted therapies |
4.2.3 Rising investments in biomedical research and development |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for the use of patient-derived xenograft models |
4.3.2 High cost associated with the development and maintenance of PDX models |
4.3.3 Ethical concerns related to the use of animal models in research |
5 Poland Patient Derived Xenograft (PDX) Models Market Trends |
6 Poland Patient Derived Xenograft (PDX) Models Market, By Types |
6.1 Poland Patient Derived Xenograft (PDX) Models Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Type, 2022-2032F |
6.1.3 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Mice Models, 2022-2032F |
6.1.4 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Rat Models, 2022-2032F |
6.2 Poland Patient Derived Xenograft (PDX) Models Market, By Tumor Type |
6.2.1 Overview and Analysis |
6.2.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Gastrointestinal Tumor Models, 2022-2032F |
6.2.3 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Lung Tumor Models, 2022-2032F |
6.2.4 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Haematological Tumor Models, 2022-2032F |
6.3 Poland Patient Derived Xenograft (PDX) Models Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Preclinical Drug Development, 2022-2032F |
6.3.3 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Precision Medicine, 2022-2032F |
6.3.4 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Co-Clinical Trials, 2022-2032F |
6.3.5 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Basic Cancer Research, 2022-2032F |
6.3.6 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Biomarker Analysis, 2022-2032F |
6.3.7 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Oncology Research, 2022-2032F |
6.4 Poland Patient Derived Xenograft (PDX) Models Market, By Technique |
6.4.1 Overview and Analysis |
6.4.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Heterotopic Implantation, 2022-2032F |
6.4.3 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Orthotropic Implantation, 2022-2032F |
6.5 Poland Patient Derived Xenograft (PDX) Models Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Academic and Research Organizations, 2022-2032F |
6.5.3 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Contract Research Organizations, 2022-2032F |
6.5.4 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Pharmaceutical and Biotechnological Companies, 2022-2032F |
6.5.5 Poland Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Others, 2022-2032F |
7 Poland Patient Derived Xenograft (PDX) Models Market Import-Export Trade Statistics |
7.1 Poland Patient Derived Xenograft (PDX) Models Market Export to Major Countries |
7.2 Poland Patient Derived Xenograft (PDX) Models Market Imports from Major Countries |
8 Poland Patient Derived Xenograft (PDX) Models Market Key Performance Indicators |
8.1 Number of collaborations between research institutions and pharmaceutical companies for PDX model development |
8.2 Percentage of cancer research projects in Poland utilizing PDX models |
8.3 Adoption rate of PDX models in preclinical drug testing in the Polish pharmaceutical industry |
9 Poland Patient Derived Xenograft (PDX) Models Market - Opportunity Assessment |
9.1 Poland Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Type, 2022 & 2032F |
9.2 Poland Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Tumor Type, 2022 & 2032F |
9.3 Poland Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Application, 2022 & 2032F |
9.4 Poland Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Technique, 2022 & 2032F |
9.5 Poland Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Poland Patient Derived Xenograft (PDX) Models Market - Competitive Landscape |
10.1 Poland Patient Derived Xenograft (PDX) Models Market Revenue Share, By Companies, 2025 |
10.2 Poland Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here